Dogwood Therapeutics (Nasdaq: DWTX) announced the completion of patient enrollment in its Phase 2b clinical trial evaluating Halneuron® for chemotherapy-induced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE